| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
This peptide is an immunodominant epitope restricted by MHC class I H-2Db molecules and is presented to cytotoxic T lymphocytes (CD8+ T cells). Its primary target is the T cell receptor (TCR) on CD8+ T cells.
|
|---|---|
| ln Vitro |
LCMV gp33-41 TFA is not a drug but an immunological tool used to study antiviral T cell responses. It is used in T-cell activation assays to stimulate specific CD8+ T cells in vitro and measure their functional responses including proliferation, cytokine production, and cytotoxicity.
|
| ln Vivo |
In vivo, LCMV gp33-41 is used to study adaptive immune responses by immunizing animals to generate antigen-specific CD8+ T cells. It is widely applied in vaccine research and investigations of T-cell receptor specificity, helping to advance antiviral and immunotherapeutic strategies.
|
| Enzyme Assay |
Non-cell binding assays for peptide-MHC interactions are performed using surface plasmon resonance (SPR) or biolayer interferometry (BLI). For SPR, recombinant H-2Db MHC class I molecules are biotinylated and immobilized on a streptavidin-coated sensor chip. The LCMV gp33-41 peptide (KAVYNFATC) is prepared in running buffer (10 mM HEPES, 150 mM NaCl, 0.005% Tween-20, pH 7.4). Serial dilutions of the peptide (0.1-100 uM) are flowed over the chip. Association (3 minutes) and dissociation (5 minutes) phases are monitored. Binding affinity (KD) is calculated by fitting sensorgrams to a 1:1 Langmuir binding model. Alternatively, peptide binding to purified H-2Db molecules can be measured using a competition binding assay with a radiolabeled standard peptide, where the unlabeled gp33-41 peptide competes for binding, and IC50 values are determined.
|
| Cell Assay |
Cellular assays are performed using splenocytes or purified CD8+ T cells from LCMV-infected or immunized mice. For T cell activation assays, cells are seeded in 96-well plates (2×10⁵ cells/well) and stimulated with LCMV gp33-41 peptide at concentrations ranging from 1 pM to 10 uM for 24-72 hours. T cell activation is assessed by measuring IFN-gamma production using ELISA or ELISpot. For proliferation assays, cells are labeled with CFSE (5-10 uM) prior to peptide stimulation, and proliferation (CFSE dilution) is analyzed by flow cytometry after 3-5 days. Cytotoxicity assays are performed using peptide-pulsed target cells. Naïve splenocytes are pulsed with the peptide (1-10 uM for 1 hour) and then labeled with a high concentration of CFSE (5 uM). Control unpulsed cells are labeled with a low concentration of CFSE (0.5 uM). These are mixed at a 1:1 ratio and co-cultured with effector CD8+ T cells for 4-6 hours. The specific lysis is quantified by the reduction in the CFSE-high population relative to the CFSE-low population by flow cytometry. For intracellular cytokine staining, cells are treated with peptide plus Brefeldin A (3 ug/mL) for 5-6 hours, then fixed, permeabilized, and stained for IFN-gamma, TNF-alpha, and IL-2 followed by flow cytometry.
|
| Animal Protocol |
In vivo immunization protocols involve 6-8 week old female C57BL/6 mice. LCMV gp33-41 peptide is conjugated to keyhole limpet hemocyanin (KLH) via the cysteine residue and emulsified with adjuvant such as Complete Freund‘s Adjuvant (CFA) or Addavax. Mice receive subcutaneous or intraperitoneal immunization with 25-50 microg of peptide conjugate per mouse, mixed with polyinosine-polycytidylic acid (10 microg/mouse) and adjuvant. A booster dose is administered 14-21 days later with Incomplete Freund's Adjuvant (IFA). For viral infection models, mice are infected intraperitoneally with 2×10⁵ PFU of LCMV Armstrong (acute) or 2×10⁶ PFU of LCMV Clone 13 (chronic). Seven to fourteen days post-infection, mice are euthanized, and splenocytes are harvested for ex vivo analysis of T cell responses using tetramer staining for LCMV gp33-41-specific CD8+ T cells (Db/GP33 tetramer). Alternatively, for in vivo cytotoxicity assays, peptide-pulsed splenocytes labeled with a high concentration of CFSE are injected intravenously. After 12-18 hours, recipient mice are sacrificed, and the ratio of CFSE-high to CFSE-low cells in the spleen is determined by flow cytometry to calculate the percentage of specific killing mediated by GP33-specific T cells.
|
| ADME/Pharmacokinetics |
LCMV gp33-41 is a short synthetic peptide (9 amino acids: KAVYNFATC, MW ~1050 Da as TFA salt) and does not have pharmacokinetic properties as a drug. As an immunogen, its in vivo half-life is short (minutes to hours) due to rapid degradation by serum proteases. To enhance immunogenicity, the peptide is often conjugated to carrier proteins such as KLH or BSA and formulated with adjuvants that form depots, prolonging exposure to the immune system. Following immunization, peptide is taken up by antigen-presenting cells (APCs) including dendritic cells, processed, and presented via MHC class I to CD8+ T cells. Biodistribution studies have not been performed as the peptide is not a therapeutic candidate.
|
| Toxicity/Toxicokinetics |
The peptide itself has minimal direct toxicity. TFA salts are generally considered safe for research use at the low concentrations used in immunological assays. High concentrations of TFA may cause mild irritation. In animal immunization studies, no overt toxicity has been reported at the typical doses used (25-50 microg per mouse). The primary biological effects relate to immune activation, which at high doses could potentially lead to cytokine storm or autoimmune reactions, though this has not been observed at research-scale doses. As a research peptide, toxicological characterization beyond acute local inflammation at injection sites is not available.
|
| References | |
| Additional Infomation |
LCMV gp33-41 is a widely used MHC class I restricted epitope in immunological research, particularly for studying CD8+ T cell responses. The P14 TCR transgenic mouse strain, which recognizes LCMV gp33-41 in the context of H-2Db, is a key model system for investigating T cell development, activation, memory formation, and exhaustion. The peptide is extensively used in vaccine research, T-cell activation assays, investigations of adaptive immune responses, and studies of T-cell receptor specificity. It has also been used to explore mechanisms of autoimmune disease, as GP33-specific T cells can mediate immunopathology. LCMV gp33-41 serves as a valuable tool to advance antiviral strategies and immunotherapeutic development, but has not received regulatory approval for human use.
|
| Molecular Formula |
C50H74N11F3015S
|
|---|---|
| Molecular Weight |
1158.24
|
| Related CAS # |
LCMV gp33-41;151705-84-9
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~86.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8634 mL | 4.3169 mL | 8.6338 mL | |
| 5 mM | 0.1727 mL | 0.8634 mL | 1.7268 mL | |
| 10 mM | 0.0863 mL | 0.4317 mL | 0.8634 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
